OCLS: Development Agreement w/Bayer Taiwan for Microcyn(R) Technology -
Oculus Innovative Sciences receives notification from NASDAQ regarding stockholders' equity -
Oculus Innovative Sciences Receives NASDAQ Notification -
OCLS: To Present At Rodman & Renshaw Investment Conference @ 11:10 ET [delayed] -
BRIEF-Oculus Innovative Sciences Q2 results -
OCLS: Q2 Earnings Call @ 09:30 ET Today [delayed] -
Oculus introduces Microcyn wound care for US podiatry market -
Oculus Innovative Sciences Provides Clinical and Business Update -
OCLS: To Present At Merriman Curhan Ford Investor Conference @ 18:30 ET [delayed] -
Oculus launches topical wound drug in China -
OCULUS AND SINOPHARM INTRODUCE DERMACYN TO HOSPITALS IN CHINA -
Oculus Innovative Sciences and Sinopharm Announce Introduction of Dermacyn(TM) to Hospitals in China -
Oculus Innovative to reduce expenses; says operating chief to depart -
Oculus Innovative Sciences Reduces Planned Expenses While Accelerating Global Commercialization -
OCLS: Results of End-of-Phase II Meeting with FDA -